As of June 19th, 2020, the COVID-19 Therapeutics Accelerator has awarded over $60 million in grants.
Summary of Investments Made
|Funding Area||In $Millions|
|Introduction and Delivery||$0|
|Real World Evidence and Data Platforms||$5.5|
|Total to Date||$60.8 million|
Details on Clinical Development Investments
University of Oxford / Mahidol Oxford Tropical Medicine Research Unit (MORU) COPCOV Trial: Pre-exposure Prophylaxis
Using hydroxychloroquine and chloroquine. This started at the end of March and will target 40,000 health workers and hospital inpatients globally (Asian, Eastern Europe, Latin America, Africa, Europe) who may become exposed to COVID-19.
Washington University of St. Louis CROWN CORONATION Trial: Pre-exposure Prophylaxis
Using chloroquine with the intent to determine optimal dose. This will start mid-May and include up to 55,000 health workers in multiple global sites (largely Africa; also sites in Europe, North America).
Henry Ford Health System WHIP Trial: Pre-exposure Prophylaxis
Using hydroxychloroquine. This started early April and will target 3,000 health workers and first responders.
Prophylaxis Registry Trial in Low and Middle-income Countries
This allows for the collection of real-world evidence by capturing health workers’ self-initiated prophylaxis treatments and outcomes. The goal is to cover 10,000 health workers in six low- and middle-income country (LMIC) sites—partners have been identified in South Africa and Pakistan thus far. This starts in May.
University of Washington: Post-exposure Prophylaxis Using Hydroxychloroquine
This also started at the end of March and will target 2,000 close contacts of COVID-19 patients.
University of Washington high risk outpatient trial: Mild Disease Treatment
Using hydroxychloroquine, hydroxychloroquine + azithromycin, and Kaletra. This started mid-April and is targeting high risk patients in the outpatient setting in multiple sites in the US.
University of Minnesota inpatient study: Moderate Disease Treatment
Using losartan. This is targeting a small group of 220 patients early in hospitalization to prevent progression of disease and started at the end of April.
Montreal Heart Institute COLCORONA Trial: Mild Disease Treatment Using Colchicine
This started in March in Quebec and is expanding to the US and Europe with 6,000 patients.